UPB
Upstream Bio, Inc.
NASDAQ: UPB · HEALTHCARE · BIOTECHNOLOGY
$9.19
-3.36% today
Updated 2026-04-29
Market cap
$500.12M
P/E ratio
—
P/S ratio
175.23x
EPS (TTM)
$-2.66
Dividend yield
—
52W range
$7 – $34
Volume
1.0M
Upstream Bio, Inc. (UPB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.21M | $2.38M | $2.37M | $2.85M |
| Revenue growth (YoY) | — | +96.4% | -0.4% | +20.4% |
| Cost of revenue | $7000.00 | $60000.00 | $89000.00 | $188000.00 |
| Gross profit | $1.21M | $2.38M | $2.37M | $2.67M |
| Gross margin | 100.0% | 100.0% | 100.0% | 93.4% |
| R&D | $18.66M | $31.80M | $62.97M | $136.81M |
| SG&A | $6.46M | $10.70M | $17.17M | $26.41M |
| Operating income | $-23.91M | $-40.11M | $-77.76M | $-160.36M |
| Operating margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| EBITDA | $-23.90M | $-40.05M | $-77.67M | $-160.36M |
| EBITDA margin | -1972.1% | -1682.9% | -3277.4% | -5618.8% |
| EBIT | $-23.91M | $-40.11M | $-77.76M | $-160.55M |
| Interest expense | — | — | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-23.87M | $-20.54M | $-62.81M | $-143.44M |
| Net income growth (YoY) | — | +14.0% | -205.8% | -128.4% |
| Profit margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |